

SUPPLEMENTARY MATERIALS

Table S1. Antibody marker combinations used for PBMC phenotype analysis through flow cytometry.

Antibody-Marker Combination	Panel	Dilution	Species specificity	Source
CD4-FITC	A	1:200	Cat	SouthernBiotech
CD8-PE	A	1:200	Cat	SouthernBiotech
CD25-PE/Cy7 ^a	A	1:20	Cat	Dr. Gregg Dean ^c
CD134-647	A	1:20	Cat	AbD Serotec
Fas-APC/Cy7 ^b	A, B	1:200	Cat	R&D Systems
CD56-APC	B	1:20	Human	BioLegend
CD14-PE	B	1:40	Human	Caltag Medsystems
CD21-PE/Cy7	B	1:20	Human	BD Pharmingen
MHCII-FITC	B	1:20	Human	BD Pharmingen

a = antibody conjugated to fluorophore with an Abcam conjugation kit (ab102903), b = antibody conjugated to fluorophore with an Abcam conjugation kit (ab102859), c = Colorado State University.

Table S2. FFV prevalence and chi-square analysis data for CKD studies. Five cats were omitted from sex-specific analyses due to lack of sex data.

Prevalence Data							Chi-square (X ²) Data				
All		FFV+		FFV-		Total	Subgroup	Prevalence	Variable	X ² Statistic	P-value
	CKD+	59	47%	28	22%	87	All	67%	Sex vs. FFV	0.000	1.000
CKD-	25	20%	13	10%	38	CKD+FFV+	68%	(Sex CKD+) vs. FFV	0.142	0.707	
Total	84	67%	41	33%	125	CKD-FFV+	66%	(Sex CKD-) vs. FFV	0.468	0.494	
Male		FFV+		FFV-		Total	Subgroup	Prevalence	Variable	X ² Statistic	P-value
	CKD+	27	48%	10	18%	37	M FFV+	68%	Sex vs. CKD	0.091	0.763
CKD-	11	20%	8	14%	19	M CKD+FFV+	73%	(Sex FFV+) vs. CKD	0.002	0.967	
Total	38	68%	18	32%	56	M CKD-FFV+	58%	(Sex FFV-) vs. CKD	0.845	0.358	
Female		FFV+		FFV-		Total	Subgroup	Prevalence	Variable	X ² Statistic	P-value
	CKD+	30	47%	15	23%	45	F FFV+	69%	FFV vs. CKD	0.039	0.844
CKD-	14	22%	5	8%	19	F CKD+FFV+	67%	(FFV M) vs CKD	0.709	0.400	
Total	44	69%	20	31%	64	F CKD-FFV+	74%	(FFV F) vs. CKD	0.067	0.796	